Cynata Therapeutics Ltd
CYP
Company Profile
Business description
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.
Contact
100 Cubitt Street
Level 3
CremorneVIC3121
AUST: +61 370676940
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
2
Stocks News & Analysis
stocks
ASX reporting season wrap: CBA, JB Hi-Fi, REA and more
A round up of notable stories and reactions as ASX earnings season gathers steam.
stocks
Market overreacts to soft guidance from ASX share
Shares undervalued after they plunge following results.
stocks
CBA earnings: The only thing that puzzles us is the share price
No surprises in fiscal 2025 earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,149.10 | 46.00 | 0.51% |
| CAC 40 | 7,804.97 | 51.55 | 0.66% |
| DAX 40 | 24,185.59 | 160.81 | 0.67% |
| Dow JONES (US) | 44,922.27 | 463.66 | 1.04% |
| FTSE 100 | 9,166.21 | 0.98 | 0.01% |
| HKSE | 25,493.66 | 120.01 | -0.47% |
| NASDAQ | 21,713.14 | 31.24 | 0.14% |
| Nikkei 225 | 42,649.26 | 625.41 | -1.45% |
| NZX 50 Index | 12,834.08 | 67.54 | 0.53% |
| S&P 500 | 6,466.58 | 20.82 | 0.32% |
| S&P/ASX 200 | 8,873.80 | 46.70 | 0.53% |
| SSE Composite Index | 3,667.53 | 15.94 | -0.43% |